FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lisa Von Moltke

Research Profile

Chemicals & Drugs

Anatomy

Microsomes, Liver

Physiology

Co-author Network

Publications

TOP 3
David J Greenblatt; Yanli Zhao; Karthik Venkatakrishnan; Su X Duan; Jerold S Harmatz; Sarah J Parent; Michael H Court; Lisa L Von Moltke
Mechanism of cytochrome P450-3A inhibition by ketoconazole.
Donna Reece; Dan Sullivan; Sagar Lonial; Ann F Mohrbacher; Gurkamal Chatta; Chaim Shustik; Howard Burris; Karthik Venkatakrishnan; Rachel Neuwirth; William J Riordan; Michael Karol; Lisa L Von Moltke; Milin Acharya; Peter Zannikos; A Keith Stewart
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Karthik Venkatakrishnan; Michael D Pickard; Lisa L Von Moltke
A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lisa Von Moltke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: David J Greenblatt; Yanli Zhao; Karthik Venkatakrishnan; Su X Duan; Jerold S Harmatz; Sarah J Parent; Michael H Court; Lisa L Von Moltke
Mechanism of cytochrome P450-3A inhibition by ketoconazole.
The Journal of pharmacy and pharmacology 2011;63(2):214-21.
2011: Donna Reece; Dan Sullivan; Sagar Lonial; Ann F Mohrbacher; Gurkamal Chatta; Chaim Shustik; Howard Burris; Karthik Venkatakrishnan; Rachel Neuwirth; William J Riordan; Michael Karol; Lisa L Von Moltke; Milin Acharya; Peter Zannikos; A Keith Stewart
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Cancer chemotherapy and pharmacology 2011;67(1):57-67.
2010: Karthik Venkatakrishnan; Michael D Pickard; Lisa L Von Moltke
A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
Clinical pharmacokinetics 2010;49(11):703-27.
2010: David J Greenblatt; Karthik Venkatakrishnan; Jerold S Harmatz; Sarah J Parent; Lisa L Von Moltke
Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.
Xenobiotica; the fate of foreign compounds in biological systems 2010;40(10):713-20.
2010: L Oleson; Lisa L Von Moltke; David J Greenblatt; Michael H Court
Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism.
Xenobiotica; the fate of foreign compounds in biological systems 2010;40(2):146-62.
2010: Chuang Lu; Suresh K Balani; Mark G Qian; Shimoga R Prakash; Patricia S Ducray; Lisa L Von Moltke
Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
The Journal of pharmacology and experimental therapeutics 2010;332(2):562-8.
2008: Tamsin Knox; Lauren Oleson; Lisa L Von Moltke; Rhonda C Kaufman; Christine Wanke; David J Greenblatt
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
Journal of acquired immune deficiency syndromes (1999) 2008;49(4):358-68.
2008: David J Greenblatt; Lisa L Von Moltke
Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs.
Journal of clinical pharmacology 2008;48(11):1350-5.
2008: John S Markowitz; Lisa L Von Moltke; Jennifer L Donovan
Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations.
Molecular nutrition & food research 2008;52(7):747-54.
2007: Michael D Perloff; Lisa L Von Moltke; Jeanne M Fahey; David J Greenblatt
Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells.
The Journal of pharmacy and pharmacology 2007;59(7):947-53.
2007: R M Cysneiros; Dora Farkas; Jerold S Harmatz; Lisa L Von Moltke; David J Greenblatt
Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine.
Clinical pharmacology and therapeutics 2007;82(1):54-62.
2007: Kristina K Wolf; Sheryl G Wood; Jenna L Allard; Jane A Hunt; Nadia Gorman; Brooke W Walton-Strong; Juliana G Szakacs; Su X Duan; Qin Hao; Michael H Court; Lisa L Von Moltke; David J Greenblatt; Vsevolod E Kostrubsky; Elizabeth H Jeffery; Steven A Wrighton; Frank J Gonzalez; Peter R Sinclair; Jacqueline F Sinclair
Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(7):1223-31.
2006: Ping He; Michael H Court; David J Greenblatt; Lisa L Von Moltke
Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity.
Journal of clinical pharmacology 2006;46(11):1356-69.
2006: Ping He; Michael H Court; David J Greenblatt; Lisa L Von Moltke
Factors influencing midazolam hydroxylation activity in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(7):1198-207.
2006: Hugo Girard; Lyne Villeneuve; Michael H Court; Louis-Charles Fortier; Patrick Caron; Qin Hao; Lisa L Von Moltke; David J Greenblatt; Chantal Guillemette
The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(7):1220-8.
2006: Kirk M Bertelsen; David J Greenblatt; Lisa L Von Moltke
Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers.
Biopharmaceutics & drug disposition 2006;27(5):219-27.
2006: Leah M Hesse; David J Greenblatt; Lisa L Von Moltke; Michael H Court
Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers.
Journal of clinical pharmacology 2006;46(5):567-76.
2006: Kerry E Culm-Merdek; Lisa L Von Moltke; Lu Gan; Kelly A Horan; Robyn Reynolds; Jerold S Harmatz; Michael H Court; David J Greenblatt
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir.
Clinical pharmacology and therapeutics 2006;79(3):243-54.
2006: David J Greenblatt; Richard A Leigh-Pemberton; Lisa L Von Moltke
In vitro interactions of water-soluble garlic components with human cytochromes p450.
The Journal of nutrition 2006;136(3 Suppl):806S-809S.
2006: David J Greenblatt; Lisa L Von Moltke; Yan Luo; Elke S Perloff; Kelly A Horan; Allison Bruce; Robyn C Reynolds; Jerold S Harmatz; Bharathi Avula; Ikhlas A Khan; Peter Goldman
Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate.
Journal of clinical pharmacology 2006;46(2):214-21.
2006: David J Greenblatt; Lisa L Von Moltke; Elke S Perloff; Yan Luo; Jerold S Harmatz; Miguel A Zinny
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies.
Clinical pharmacology and therapeutics 2006;79(1):125-33.
2005: Kristina K Wolf; Sheryl G Wood; Jane A Hunt; Brooke W Walton-Strong; Kazuto Yasuda; Lubin Lan; Su X Duan; Qin Hao; Steven A Wrighton; Elizabeth H Jeffery; Ronald M Evans; Juliana G Szakacs; Lisa L Von Moltke; David J Greenblatt; Michael H Court; Erin G Schuetz; Peter R Sinclair; Jacqueline F Sinclair
Role of the nuclear receptor pregnane X receptor in acetaminophen hepatotoxicity.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(12):1827-36.
2005: Kerry E Culm-Merdek; Lisa L Von Moltke; Jerold S Harmatz; David J Greenblatt
Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
British journal of clinical pharmacology 2005;60(5):486-93.
2005: Hugo Girard; Jean Thibaudeau; Michael H Court; Louis-Charles Fortier; Lyne Villeneuve; Patrick Caron; Qin Hao; Lisa L Von Moltke; David J Greenblatt; Chantal Guillemette
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver.
Hepatology (Baltimore, Md.) 2005;42(2):448-57.
2005: Elke S Perloff; Su X Duan; Paul R Skolnik; David J Greenblatt; Lisa L Von Moltke
Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(6):764-70.
2005: Soundararajan Krishnaswamy; Qin Hao; Abdul Al-Rohaimi; Leah M Hesse; Lisa L Von Moltke; David J Greenblatt; Michael H Court
UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation.
The Journal of pharmacology and experimental therapeutics 2005;313(3):1331-9.
2005: Soundararajan Krishnaswamy; Qin Hao; Abdul Al-Rohaimi; Leah M Hesse; Lisa L Von Moltke; David J Greenblatt; Michael H Court
UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).
The Journal of pharmacology and experimental therapeutics 2005;313(3):1340-6.
2005: Ping He; Michael H Court; David J Greenblatt; Lisa L Von Moltke
Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
Clinical pharmacology and therapeutics 2005;77(5):373-87.
2005: David J Greenblatt; Lisa L Von Moltke
Interaction of warfarin with drugs, natural substances, and foods.
Journal of clinical pharmacology 2005;45(2):127-32.
2005: Monette M Cotreau; Lisa L Von Moltke; David J Greenblatt
The influence of age and sex on the clearance of cytochrome P450 3A substrates.
Clinical pharmacokinetics 2005;44(1):33-60.
2004: David J Greenblatt; Jerold S Harmatz; Lisa L Von Moltke; C Eugene Wright; Richard I Shader
Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.
Clinical pharmacology and therapeutics 2004;76(5):467-79.
2004: Tanios S Bekaii-Saab; Michael D Perloff; James L Weemhoff; David J Greenblatt; Lisa L Von Moltke
Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A.
Biopharmaceutics & drug disposition 2004;25(7):283-9.
2004: Lisa L Von Moltke; James L Weemhoff; Erdal Bedir; Ikhlas A Khan; Jerold S Harmatz; Peter Goldman; David J Greenblatt
Inhibition of human cytochromes P450 by components of Ginkgo biloba.
The Journal of pharmacy and pharmacology 2004;56(8):1039-44.
2004: Kiran C Patki; David J Greenblatt; Lisa L Von Moltke
Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
The Journal of pharmacy and pharmacology 2004;56(8):963-6.
2004: Hugo Girard; Michael H Court; Olivier Bernard; Louis-Charles Fortier; Lyne Villeneuve; Qin Hao; David J Greenblatt; Lisa L Von Moltke; Louis Perussed; Chantal Guillemette
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.
Pharmacogenetics 2004;14(8):501-15.
2004: Soundararajan Krishnaswamy; Qin Hao; Lisa L Von Moltke; David J Greenblatt; Michael H Court
Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(8):862-9.
2004: Lisa L Von Moltke; Brian W Granda; Jeffrey M Grassi; Michael D Perloff; Daesety Vishnuvardhan; David J Greenblatt
Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(8):800-4.
2004: Tim Mitin; Lisa L Von Moltke; Michael H Court; David J Greenblatt
Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(8):779-82.
2004: Michael H Court; Qin Hao; Soundararajan Krishnaswamy; Tanios Bekaii-Saab; Abdul Al-Rohaimi; Lisa L Von Moltke; David J Greenblatt
UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.
The Journal of pharmacology and experimental therapeutics 2004;310(2):656-65.
2004: Geetha Ramachandran; Elke S Perloff; Lisa L Von Moltke; Soumya Swaminathan; Christine A Wanke; David J Greenblatt
Analysis of generic antiretroviral formulations manufactured in India.
AIDS (London, England) 2004;18(10):1482-4.
2004: Jill S Warrington; Michael H Court; David J Greenblatt; Lisa L Von Moltke
Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats.
The Journal of pharmacy and pharmacology 2004;56(6):819-25.
2004: Jill S Warrington; David J Greenblatt; Lisa L Von Moltke
Role of CYP3A enzymes in the biotransformation of triazolam in rat liver.
Xenobiotica; the fate of foreign compounds in biological systems 2004;34(5):463-71.
2004: Jill S Warrington; David J Greenblatt; Lisa L Von Moltke
The effect of age on P-glycoprotein expression and function in the Fischer-344 rat.
The Journal of pharmacology and experimental therapeutics 2004;309(2):730-6.
2004: Jill S Warrington; David J Greenblatt; Lisa L Von Moltke
Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney.
The Journal of pharmacology and experimental therapeutics 2004;309(2):720-9.
2004: Leah M Hesse; Ping He; Soundararajan Krishnaswamy; Qin Hao; Kirk Hogan; Lisa L Von Moltke; David J Greenblatt; Michael H Court
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Pharmacogenetics 2004;14(4):225-38.
2004: Kiran C Patki; Lisa L Von Moltke; Jerold S Harmatz; Leah M Hesse; Michael H Court; David J Greenblatt
Effect of age on in vitro triazolam biotransformation in male human liver microsomes.
The Journal of pharmacology and experimental therapeutics 2004;308(3):874-9.
2004: Michael D Perloff; Lisa L Von Moltke; David J Greenblatt
Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.
Xenobiotica; the fate of foreign compounds in biological systems 2004;34(2):133-50.
2003: Jill S Warrington; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader; David J Greenblatt
The effect of age on sildenafil biotransformation in rat and mouse liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(11):1306-9.
2003: Karthik Venkatakrishnan; Lisa L Von Moltke; R Scott Obach; David J Greenblatt
Drug metabolism and drug interactions: application and clinical value of in vitro models.
Current drug metabolism 2003;4(5):423-59.
2003: Lisa L Von Moltke; David J Greenblatt
Medication dependence and anxiety.
Dialogues in clinical neuroscience 2003;5(3):237-45.
2003: Leah M Hesse; Yumiko Sakai; Daesety Vishnuvardhan; Albert P Li; Lisa L Von Moltke; David J Greenblatt
Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin.
The Journal of pharmacy and pharmacology 2003;55(9):1229-39.
2003: Michael H Court; Soundararajan Krishnaswamy; Qin Hao; Su X Duan; Christopher J Patten; Lisa L Von Moltke; David J Greenblatt
Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1125-33.
2003: Joel O Olubodun; Hermann R Ochs; Lisa L Von Moltke; Ronenn Roubenoff; Leah M Hesse; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.
British journal of clinical pharmacology 2003;56(3):297-304.
2003: Michael D Perloff; Elke Störmer; Lisa L Von Moltke; David J Greenblatt
Rapid assessment of P-glycoprotein inhibition and induction in vitro.
Pharmaceutical research 2003;20(8):1177-83.
2003: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Gengsheng Chen; James L Weemhoff; Cheng Jen; Charles J Kelley; Barbara W LeDuc; Miguel A Zinny
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
Clinical pharmacology and therapeutics 2003;74(2):121-9.
2003: Kiran C Patki; Lisa L Von Moltke; David J Greenblatt
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(7):938-44.
2003: Michael D Perloff; Lisa L Von Moltke; David J Greenblatt
Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
Xenobiotica; the fate of foreign compounds in biological systems 2003;33(4):365-77.
2003: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Steven M Fogelman; Gengsheng Chen; Jennifer A Graf; Polyxane Mertzanis; Susan Byron; Kerry E Culm; Brian W Granda; Johanna Daily; Richard I Shader
Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.
Journal of clinical pharmacology 2003;43(4):414-22.
2003: James L Weemhoff; Lisa L Von Moltke; Clemens Richert; Leah M Hesse; Jerold S Harmatz; David J Greenblatt
Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
The Journal of pharmacy and pharmacology 2003;55(3):381-6.
2003: David J Greenblatt; Lisa L Von Moltke; Gina M Giancarlo; Daniel A Garteiz
Human cytochromes mediating gepirone biotransformation at low substrate concentrations.
Biopharmaceutics & drug disposition 2003;24(2):87-94.
2003: Kirk M Bertelsen; Karthik Venkatakrishnan; Lisa L Von Moltke; R Scott Obach; David J Greenblatt
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(3):289-93.
2003: Soundararajan Krishnaswamy; Su X Duan; Lisa L Von Moltke; David J Greenblatt; James L Sudmeier; William W Bachovchin; Michael H Court
Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences.
Xenobiotica; the fate of foreign compounds in biological systems 2003;33(2):169-80.
2003: Leah M Hesse; Lisa L Von Moltke; David J Greenblatt
Clinically important drug interactions with zopiclone, zolpidem and zaleplon.
CNS drugs 2003;17(7):513-32.
2003: Soundararajan Krishnaswamy; Su X Duan; Lisa L Von Moltke; David J Greenblatt; Michael H Court
Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(1):133-9.
2002: Lisa L Von Moltke; James L Weemhoff; Michael D Perloff; Leah M Hesse; Jerold S Harmatz; Barbara F Roth-Schechter; David J Greenblatt
Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein.
Biopharmaceutics & drug disposition 2002;23(9):361-7.
2002: Thanh Huu Tran; Lisa L Von Moltke; Karthik Venkatakrishnan; Brian W Granda; Megan A Gibbs; R Scott Obach; Jerold S Harmatz; David J Greenblatt
Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(12):1441-5.
2002: Michael D Perloff; Lisa L Von Moltke; David J Greenblatt
Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.
Journal of clinical pharmacology 2002;42(11):1269-74.
2002: Michael H Court; Su X Duan; Chantal Guillemette; Kim Journault; Soundararajan Krishnaswamy; Lisa L Von Moltke; David J Greenblatt
Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(11):1257-65.
2002: Joel O Olubodun; Hermann R Ochs; Volker Trüten; Arno Klein; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use.
Journal of clinical pharmacology 2002;42(10):1142-6.
2002: Tsutomu Kotegawa; Bart E Laurijssens; Lisa L Von Moltke; Monette M Cotreau; Michael D Perloff; Karthik Venkatakrishnan; Jill S Warrington; Brian W Granda; Jerold S Harmatz; David J Greenblatt
In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.
The Journal of pharmacology and experimental therapeutics 2002;302(3):1228-37.
2002: Elke Störmer; Lisa L Von Moltke; Michael D Perloff; David J Greenblatt
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
Pharmaceutical research 2002;19(7):1038-45.
2002: Karthik Venkatakrishnan; Lisa L Von Moltke; David J Greenblatt
Evaluation of Supermix as an in vitro model of human liver microsomal drug metabolism.
Biopharmaceutics & drug disposition 2002;23(5):183-90.
2002: Jill S Warrington; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):655-7.
2001: Michael D Perloff; Lisa L Von Moltke; Elke Störmer; Richard I Shader; David J Greenblatt
Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.
British journal of pharmacology 2001;134(8):1601-8.
2001: Michael H Court; Su X Duan; Lisa L Von Moltke; D J Greenblatt; C J Patten; J O Miners; P I Mackenzie
Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms.
The Journal of pharmacology and experimental therapeutics 2001;299(3):998-1006.
2001: Michael D Perloff; Lisa L Von Moltke; J E Marchand; David J Greenblatt
Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line.
Journal of pharmaceutical sciences 2001;90(11):1829-37.
2001: Karthik Venkatakrishnan; Lisa L Von Moltke; David J Greenblatt
Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.
Journal of clinical pharmacology 2001;41(11):1149-79.
2001: Karthik Venkatakrishnan; J Schmider; Jerold S Harmatz; Bruce L Ehrenberg; Lisa L Von Moltke; Jennifer A Graf; Polyxane Mertzanis; Kathleen E Corbett; M C Rodriguez; Richard I Shader; David J Greenblatt
Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies.
Journal of clinical pharmacology 2001;41(10):1043-54.
2001: Lisa L Von Moltke; David J Greenblatt; M K Romach; E M Sellers
Cognitive toxicity of drugs used in the elderly.
Dialogues in clinical neuroscience 2001;3(3):181-90.
2001: Lisa L Von Moltke; David J Greenblatt; Gina M Giancarlo; Brian W Granda; Jerold S Harmatz; Richard I Shader
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(8):1102-9.
2001: Elke Störmer; Lisa L Von Moltke; Michael D Perloff; David J Greenblatt
P-glycoprotein interactions of nefazodone and trazodone in cell culture.
Journal of clinical pharmacology 2001;41(7):708-14.
2001: Elke Störmer; Michael D Perloff; Lisa L Von Moltke; David J Greenblatt
Methadone inhibits rhodamine123 transport in Caco-2 cells.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(7):954-6.
2001: Gina M Giancarlo; Karthik Venkatakrishnan; Brian W Granda; Lisa L Von Moltke; David J Greenblatt
Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
European journal of clinical pharmacology 2001;57(1):31-6.
2001: Karthik Venkatakrishnan; Lisa L Von Moltke; David J Greenblatt
Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
The Journal of pharmacology and experimental therapeutics 2001;297(1):326-37.
2001: Leah M Hesse; Karthik Venkatakrishnan; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(2):133-40.
2001: Leah M Hesse; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(2):100-2.
2001: Monette M Cotreau; Lisa L Von Moltke; Jerold S Harmatz; David J Greenblatt
Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen.
Pharmacology 2001;63(4):210-9.
2001: Lisa L Von Moltke; David J Greenblatt; Brian W Granda; Gina M Giancarlo; Su X Duan; Johanna Daily; Jerold S Harmatz; Richard I Shader
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
Journal of clinical pharmacology 2001;41(1):85-91.
2000: Karthik Venkatakrishnan; Lisa L Von Moltke; Michael H Court; Jerold S Harmatz; C L Crespi; David J Greenblatt
Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(12):1493-504.
2000: Elke Störmer; Lisa L Von Moltke; David J Greenblatt
Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism.
The Journal of pharmacology and experimental therapeutics 2000;295(2):793-801.
2000: Leah M Hesse; Karthik Venkatakrishnan; Michael H Court; Lisa L Von Moltke; Su X Duan; Richard I Shader; David J Greenblatt
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1176-83.
2000: Elke Störmer; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1168-75.
2000: David J Greenblatt; Lisa L Von Moltke; Bruce L Ehrenberg; Jerold S Harmatz; Kathleen E Corbett; D W Wallace; Richard I Shader
Kinetics and dynamics of lorazepam during and after continuous intravenous infusion.
Critical care medicine 2000;28(8):2750-7.
2000: Michael D Perloff; Lisa L Von Moltke; Jeanne M Fahey; Johanna Daily; David J Greenblatt
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
AIDS (London, England) 2000;14(9):1287-9.
2000: Lisa L Von Moltke; AL Durol; Su X Duan; David J Greenblatt
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
European journal of clinical pharmacology 2000;56(3):259-61.
2000: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; AL Durol; Johanna Daily; Jennifer A Graf; Polyxane Mertzanis; J L Hoffman; Richard I Shader
Differential impairment of triazolam and zolpidem clearance by ritonavir.
Journal of acquired immune deficiency syndromes (1999) 2000;24(2):129-36.
2000: David J Greenblatt; Jerold S Harmatz; Lisa L Von Moltke; C Eugene Wright; AL Durol; L M Harrel-Joseph; Richard I Shader
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.
The Journal of pharmacology and experimental therapeutics 2000;293(2):435-43.
2000: Karthik Venkatakrishnan; Lisa L Von Moltke; R Scott Obach; David J Greenblatt
Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro.
The Journal of pharmacology and experimental therapeutics 2000;293(2):343-50.
2000: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; AL Durol; Johanna Daily; Jennifer A Graf; Polyxane Mertzanis; J L Hoffman; Richard I Shader
Alprazolam-ritonavir interaction: implications for product labeling.
Clinical pharmacology and therapeutics 2000;67(4):335-41.
2000: A Zalma; Lisa L Von Moltke; Brian W Granda; Jerold S Harmatz; Richard I Shader; David J Greenblatt
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Biological psychiatry 2000;47(7):655-61.
2000: Jill S Warrington; Richard I Shader; Lisa L Von Moltke; David J Greenblatt
In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(4):392-7.
2000: J S Warrington; J W Poku; Lisa L Von Moltke; Richard I Shader; Jerold S Harmatz; David J Greenblatt
Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
The Journal of pharmacology and experimental therapeutics 2000;292(3):1024-31.
2000: Karthik Venkatakrishnan; Lisa L Von Moltke; David J Greenblatt
Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
Clinical pharmacokinetics 2000;38(2):111-80.
2000: Lisa L Von Moltke; T H Tran; Monette M Cotreau; David J Greenblatt
Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region.
Journal of clinical pharmacology 2000;40(2):200-4.
2000: Michael D Perloff; Lisa L Von Moltke; M H Court; Tsutomu Kotegawa; Richard I Shader; David J Greenblatt
Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
The Journal of pharmacology and experimental therapeutics 2000;292(2):618-28.
2000: Monette M Cotreau; Lisa L Von Moltke; M C Beinfeld; David J Greenblatt
Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level.
Journal of pharmacological and toxicological methods 2000;43(1):41-54.
1999: Karthik Venkatakrishnan; Lisa L Von Moltke; David J Greenblatt
CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(12):1519-22.
1999: Richard I Shader; Brian W Granda; Lisa L Von Moltke; Gina M Giancarlo; David J Greenblatt
Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast.
Biopharmaceutics & drug disposition 1999;20(8):385-8.
1999: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader
Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.
Journal of clinical psychopharmacology 1999;19(5 Suppl 1):23S-35S.
1999: Lisa L Von Moltke; David J Greenblatt; Jeffrey M Grassi; Brian W Granda; Karthik Venkatakrishnan; Su X Duan; Steven M Fogelman; Jerold S Harmatz; Richard I Shader
Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.
Biological psychiatry 1999;46(6):839-49.
1999: Lisa L Von Moltke; David J Greenblatt; Brian W Granda; Jeffrey M Grassi; J Schmider; Jerold S Harmatz; Richard I Shader
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.
Psychopharmacology 1999;145(1):113-22.
1999: Lisa L Von Moltke; David J Greenblatt; Brian W Granda; Su X Duan; Jeffrey M Grassi; Karthik Venkatakrishnan; Jerold S Harmatz; Richard I Shader
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.
British journal of clinical pharmacology 1999;48(1):89-97.
1999: Karthik Venkatakrishnan; Lisa L Von Moltke; David J Greenblatt
Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Journal of clinical pharmacology 1999;39(6):567-77.
1999: Michael D Perloff; Lisa L Von Moltke; Monette M Cotreau; David J Greenblatt
Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes.
Biochemical pharmacology 1999;57(11):1227-32.
1999: J Schmider; Lisa L Von Moltke; Richard I Shader; Jerold S Harmatz; David J Greenblatt
Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.
Drug metabolism reviews 1999;31(2):545-60.
1999: Steven M Fogelman; J Schmider; Karthik Venkatakrishnan; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader; David J Greenblatt
O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;20(5):480-90.
1998: Karthik Venkatakrishnan; Lisa L Von Moltke; David J Greenblatt
Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity.
Journal of pharmaceutical sciences 1998;87(12):1502-7.
1998: Lisa L Von Moltke; David J Greenblatt; Jeffrey M Grassi; Brian W Granda; Steven M Fogelman; Jerold S Harmatz; S J Kramer; L F Fabre; Richard I Shader
Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects.
Psychopharmacology 1998;140(3):293-9.
1998: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Polyxane Mertzanis; Jennifer A Graf; AL Durol; M Counihan; B Roth-Schechter; Richard I Shader
Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.
Clinical pharmacology and therapeutics 1998;64(6):661-71.
1998: Brian W Granda; Gina M Giancarlo; Lisa L Von Moltke; David J Greenblatt
Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography.
Journal of pharmacological and toxicological methods 1998;40(4):235-9.
1998: David J Greenblatt; Jerold S Harmatz; Lisa L Von Moltke; Bruce L Ehrenberg; L Harrel; Kathleen E Corbett; M Counihan; Jennifer A Graf; Mona Darwish; Polyxane Mertzanis; PT Martin; WH Cevallos; Richard I Shader
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.
Clinical pharmacology and therapeutics 1998;64(5):553-61.
1998: Lisa L Von Moltke; David J Greenblatt; Su X Duan; Johanna Daily; Jerold S Harmatz; Richard I Shader
Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
Journal of pharmaceutical sciences 1998;87(10):1184-9.
1998: Lisa L Von Moltke; David J Greenblatt; Jeffrey M Grassi; Brian W Granda; Karthik Venkatakrishnan; J Schmider; Jerold S Harmatz; Richard I Shader
Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
The Journal of pharmacy and pharmacology 1998;50(9):997-1004.
1998: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; M Counihan; Jennifer A Graf; AL Durol; Polyxane Mertzanis; Su X Duan; C Eugene Wright; Richard I Shader
Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Clinical pharmacology and therapeutics 1998;64(3):278-85.
1998: David J Greenblatt; C Eugene Wright; Lisa L Von Moltke; Jerold S Harmatz; Bruce L Ehrenberg; L M Harrel; Kathleen E Corbett; M Counihan; S Tobias; Richard I Shader
Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
Clinical pharmacology and therapeutics 1998;64(3):237-47.
1998: Lisa L Von Moltke; David J Greenblatt; D A Ciraulo; Jeffrey M Grassi; Brian W Granda; Su X Duan; Jerold S Harmatz; Richard I Shader
Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine.
Journal of clinical psychopharmacology 1998;18(4):338-41.
1998: Karthik Venkatakrishnan; Lisa L Von Moltke; David J Greenblatt
Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
Journal of pharmaceutical sciences 1998;87(7):845-53.
1998: Karthik Venkatakrishnan; David J Greenblatt; Lisa L Von Moltke; Richard I Shader
Alprazolam is another substrate for human cytochrome P450-3A isoforms.
Journal of clinical psychopharmacology 1998;18(3):256.
1998: Karthik Venkatakrishnan; Lisa L Von Moltke; Su X Duan; Joseph C Fleishaker; Richard I Shader; David J Greenblatt
Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
The Journal of pharmacy and pharmacology 1998;50(3):265-74.
1998: Karthik Venkatakrishnan; David J Greenblatt; Lisa L Von Moltke; J Schmider; Jerold S Harmatz; Richard I Shader
Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.
Journal of clinical pharmacology 1998;38(2):112-21.
1998: Lisa L Von Moltke; David J Greenblatt; Jeffrey M Grassi; Brian W Granda; Su X Duan; Steven M Fogelman; Johanna Daily; Jerold S Harmatz; Richard I Shader
Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir.
Journal of clinical pharmacology 1998;38(2):106-11.
1998: Lisa L Von Moltke; David J Greenblatt; J Schmider; C Eugene Wright; Jerold S Harmatz; Richard I Shader
In vitro approaches to predicting drug interactions in vivo.
Biochemical pharmacology 1998;55(2):113-22.
1998: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader
Drug interactions with newer antidepressants: role of human cytochromes P450.
The Journal of clinical psychiatry 1998;59 Suppl 15():19-27.
1997: J Schmider; David J Greenblatt; Lisa L Von Moltke; D Karsov; Richard I Shader
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
British journal of clinical pharmacology 1997;44(5):495-8.
1997: Lisa L Von Moltke; David J Greenblatt; Su X Duan; J Schmider; C Eugene Wright; Jerold S Harmatz; Richard I Shader
Human cytochromes mediating N-demethylation of fluoxetine in vitro.
Psychopharmacology 1997;132(4):402-7.
1997: J Schmider; David J Greenblatt; Steven M Fogelman; Lisa L Von Moltke; Richard I Shader
Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.
Biopharmaceutics & drug disposition 1997;18(3):227-40.
1997: Michael H Court; Lisa L Von Moltke; Richard I Shader; David J Greenblatt
Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species.
Biopharmaceutics & drug disposition 1997;18(3):213-26.
1997: K P Charpentier; Lisa L Von Moltke; J W Poku; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction.
Biopharmaceutics & drug disposition 1997;18(2):139-49.
1997: J Schmider; David J Greenblatt; Lisa L Von Moltke; D Karsov; R Vena; H L Friedman; Richard I Shader
Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors.
Journal of clinical pharmacology 1997;37(3):193-200.
1997: Lisa L Von Moltke; Su X Duan; David J Greenblatt; Steven M Fogelman; J Schmider; Jerold S Harmatz; Richard I Shader
Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms.
Biological psychiatry 1997;41(3):377-80.
1996: Lisa L Von Moltke; David J Greenblatt; Su X Duan; J Schmider; L Kudchadker; Steven M Fogelman; Jerold S Harmatz; Richard I Shader
Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.
Psychopharmacology 1996;128(4):398-407.
1996: M M Cotreau-Bibbo; Lisa L Von Moltke; David J Greenblatt
Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes.
Journal of pharmaceutical sciences 1996;85(11):1180-5.
1996: David J Greenblatt; Lisa L Von Moltke; J Schmider; Jerold S Harmatz; Richard I Shader
Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.
Journal of clinical pharmacology 1996;36(9):792-8.
1996: Lisa L Von Moltke; David J Greenblatt; J Schmider; Su X Duan; C Eugene Wright; Jerold S Harmatz; Richard I Shader
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.
Journal of clinical pharmacology 1996;36(9):783-91.
1996: J Schmider; D J Greenblatt; Lisa L Von Moltke; R I Shader
Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans.
Journal of clinical psychopharmacology 1996;16(4):267-72.
1996: R I Shader; Lisa L Von Moltke; J Schmider; Jerold S Harmatz; D J Greenblatt
The clinician and drug interactions--an update.
Journal of clinical psychopharmacology 1996;16(3):197-201.
1996: J Schmider; David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader
Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation.
British journal of clinical pharmacology 1996;41(4):339-43.
1996: Lisa L Von Moltke; David J Greenblatt; Su X Duan; Jerold S Harmatz; C Eugene Wright; Richard I Shader
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.
Journal of clinical psychopharmacology 1996;16(2):104-12.
1996: J Schmider; David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Su X Duan; D Karsov; Richard I Shader
Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies.
Pharmacology 1996;52(2):125-34.
1996: Lisa L Von Moltke; David J Greenblatt; Jerold S Harmatz; Su X Duan; L M Harrel; M M Cotreau-Bibbo; Gary A Pritchard; C Eugene Wright; Richard I Shader
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
The Journal of pharmacology and experimental therapeutics 1996;276(2):370-9.
1995: J Schmider; David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; Richard I Shader
N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.
The Journal of pharmacology and experimental therapeutics 1995;275(2):592-7.
1995: Lisa L Von Moltke; David J Greenblatt; Michael H Court; Su X Duan; Jerold S Harmatz; Richard I Shader
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
Journal of clinical psychopharmacology 1995;15(2):125-31.
1995: David J Greenblatt; Lisa L Von Moltke; Jerold S Harmatz; L M Harrel; S Tobias; Richard I Shader; C Eugene Wright
Interaction of triazolam and ketoconazole.
Lancet 1995;345(8943):191.
1995: Lisa L Von Moltke; David J Greenblatt; J Schmider; Jerold S Harmatz; Richard I Shader
Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.
Clinical pharmacokinetics 1995;29 Suppl 1():33-43; discussion 43-4.
1994: Lisa L Von Moltke; David J Greenblatt; Su X Duan; Jerold S Harmatz; Richard I Shader
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
Journal of clinical pharmacology 1994;34(12):1222-7.
1994: Lisa L Von Moltke; David J Greenblatt; M M Cotreau-Bibbo; Jerold S Harmatz; Richard I Shader
Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.
British journal of clinical pharmacology 1994;38(1):23-31.
1994: Lisa L Von Moltke; David J Greenblatt; M M Cotreau-Bibbo; Su X Duan; Jerold S Harmatz; Richard I Shader
Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.
The Journal of pharmacology and experimental therapeutics 1994;268(3):1278-83.
1993: D J Greenblatt; Lisa L Von Moltke; J S Harmatz; D A Ciraulo; R I Shader
Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications.
The Journal of clinical psychiatry 1993;54 Suppl():4-11; discussion 12-4.
1993: Lisa L Von Moltke; David J Greenblatt; Jerold S Harmatz; Richard I Shader
Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes.
Pharmacology 1993;47(4):268-76.
1993: Lisa L Von Moltke; David J Greenblatt; Richard I Shader
Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications.
Clinical pharmacokinetics 1993;24(2):141-60.